QUOTE AND NEWS
StreetInsider.com  May 1  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Viropharma%2C+Inc.+%28VPHM%29+Tops+Q1+EPS+by+11c/8292709.html for the full story.
Stock Blog Hub  Apr 27  Comment 
ViroPharma Incorporated (VPHM) recently announced results from a phase II study of its candidate VP20621 (non-toxigenic Clostridium difficile), which is being developed to prevent recurrent C. difficile infections (CDI), a gastrointestinal...
StreetInsider.com  Apr 22  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/ViroPharma+%28VPHM%29+Updates+on+VP20621+Phase+2+in+CDI%3B+54%25+of+Patients+Met+Primary+Endpoint/8266755.html for the full story.
Benzinga  Apr 22  Comment 
ViroPharma Incorporated (Nasdaq: VPHM), an international biopharmaceutical company committed to developing and commercializing innovative products that address unmet medical needs and rare diseases, today announced the results of a Phase 2 study...
Benzinga  Mar 27  Comment 
Analysts at Citigroup upgraded DSW (NYSE: DSW) from “neutral” to “buy.” The target price for DSW has been raised from $72 to $74. DSW's stock closed at $63.35 yesterday. Analysts at JP Morgan upgraded ViroPharma (NASDAQ: VPHM) from...
StreetInsider.com  Mar 25  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/NHS+Wales+Begins+Offering+ViroPharma%27s+%28VPHM%29+Cinryze/8207988.html for the full story.
StreetInsider.com  Feb 27  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Viropharma%2C+Inc.+%28VPHM%29+Tops+Q4+EPS+by+7c%3B+Guides+FY+Sales+In-Line/8136693.html for the full story.
StreetInsider.com  Jan 16  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/ViroPharma+%28VPHM%29+Updates+on+Encouraging+Cinryze+Data+in+HAE/8011557.html for the full story.
StreetInsider.com  Jan 15  Comment 
UPGRADES BofA/Merrill Lynch upgrades ViroPharma (Nasdaq: VPHM) from Neutral to Buy. Credit Suisse raises Boston Scientific (NYSE: BSX) from Neutral to Outperform. Deutsche Bank boosts Cliffs Natural Resources (NYSE: CLF) from Hold to Buy, moving...
StreetInsider.com  Jan 15  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Upgrades/BofAMerrill+Lynch+Upgrades+ViroPharma+%28VPHM%29+to+Buy/8007735.html for the full story.




RELATED WIKI ARTICLES
 
TOP CONTRIBUTORS

ViroPharma Incorporated (NYSE: VPHM) is a pharmaceutical company that develops and sells two major drugs, Cinryze and Vancocin. In Octover of 2008, ViroPharma acquired Lev Pharmaceuticals, adding an injectable treatment for angiodema to its portfolio, Cinryze. Vancocin is an oral treatment for inflammation of the bowels (colitis). ViroPharma's operators are largely focused on the development and commercialization of these two products.

Business Growth

FY 2010 (ended December 31, 2010[1]

  • Net revenue increased 41% to $439 million.
  • Net income increased 88% to $126 million.

In 2010, revenue growth was driven by Cinryze, a drug used to treat hereditary angiodema, which earned revenue of $177 million for the year, up 82%. Vancocin, a drug used to treat inflammation of the bowels (colitis), brought in sales of $260 million, up 22% on the year.

Pipeline

ViroPharma's pipeline consists of developing new formulations and indications for Cinryze and Vancocin as well as working to market the drugs in other geographies.[2]

  • Cinryze: ViroPharma is partnering with Sanquin to develop a non-injectable version of Cinryze. This version has been moved through phase II trials, and is expected to initiate phase III trials by the end of 2011. In addition, ViroPharma received European approval for Cinryze in June of 2011[3] and is exploring other geographies world-wide.
  • Vancocin: ViroPharma is developing a less toxic version of Vancocin, and is currently initiating phase II trials for the treatment.

Trends and Forces

Generic Competition for ViroPharma Would Decrease Revenues

ViroPharma does not currently face significant competition for its two major drugs, Cinryze and Vancocin. However, an influx of generic competition could both lower drug prices and reduce ViroPharma's market share, decreasing the company's overall revenues. The major patent for Cinryze expires in 2015. While ViroPharma does not have any patent protection for Vancocin, much of this is due to the historical lack of a generic pathway, a gap that has been closed with the development of a regulatory pathway for follow-on biologics.[4] If companies develop generic versions of ViroPharma's drugs, revenue will decrease.

ViroPharma's Pipeline will Impact its Future Sustainability

ViroPharma is developing several different formulations and markets for its major drugs, Cinryze and Vancocin. These approvals, if attained, will extend the reach and the overall life of ViroPharma's products. However, the ability of ViroPharma to expand beyond these two drugs and diversify its product portfolio will impact its ability to maintain a sustainable business in the long-term.

Competition[5]

  • Cinryze: Cinryze does not have patent protection, but enjoys exclusivity provided by the FDA in the Orphan drug act. Once this exclusivity expires near the end of 2015, Cinryze will face generic competition.
  • Vancocin: The patents for Vancocin expired in 1996. However, Vancocin is a complex biologic drug, and any generic competition would require significant regulatory hurdles. However, on biologics could cut into ViroPharma's sales of Vancocin.

References

  1. ViroPharma Incorporated Reports Q4 2010 Financial Results
  2. VPHM 2011 10K
  3. ViroPharma’s HAE Drug Gets EU Nod
  4. Principles of Follow On Biologics
  5. ViroPharma Competition
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki